Immunization of children with secondary immunodeficiency

Esposito, Susanna; Prada, Elisabetta; Lelii, Mara; Castellazzi, Luca

doi:10.1080/21645515.2015.1039208

Cited by 16 publications

(18 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…98,103 MMR vaccination is contraindicated in the following: (i) patients with leukocyte adhesion deficiency and defects of cytotoxic granule release such as Chediak-Higashi syndrome; (ii) patients with defects of interferon (IFN) alpha or gamma production; (iii) patients receiving chemotherapy; (iv) patients receiving ongoing anti-B-cell antibody therapy; (v) HSCT patients undergoing immunosuppression or suffering from GVHD; and (vi) HIV-infected patients with CD4 T-cell lymphocyte counts <200/mm 3 .…”

Section: Measles Mumps and Rubella (Mmr) Vaccinationmentioning

confidence: 99%

“…[99][100][101][102] In HIV-infected patients, vaccination was generally well tolerated, although a transient increase in viremia and decrease in the percentage of CD4C cells (not accompanied by worsening of clinical symptoms) was reported in some studies. 100,103 Inactivated influenza vaccines do not trigger rejection episodes and should not be withheld in transplant recipients for that reason. 99,103 In summary, annual vaccination with the inactivated influenza vaccine is recommended for all immunocompromised adults.…”

Section: Influenza Vaccinationmentioning

confidence: 99%

“…100,103 Inactivated influenza vaccines do not trigger rejection episodes and should not be withheld in transplant recipients for that reason. 99,103 In summary, annual vaccination with the inactivated influenza vaccine is recommended for all immunocompromised adults. In transplant recipients, it should be administered starting 6 months after HSCT and after intensified immunosuppression in SOT recipients has been completed, including the first 2-month post-transplant period.…”

Section: Influenza Vaccinationmentioning

confidence: 99%

“…103 In HSCT patients, MMR is recommended for seronegative individuals at least 2 y after transplant, if they have no GVHD, and do not receive any immunosuppressive drugs. 103 In an outbreak situation and based upon the experience in Brazil, vaccination should be considered on an individual basis in HSCT patients at 1 y after transplant. 112 In HIV-infected patients, MMR is recommended for those with CD4 T-lymphocyte counts 200 cells/mm 3 .…”

Section: Measles Mumps and Rubella (Mmr) Vaccinationmentioning

confidence: 99%

“…The dTp is recommended for: 103,106,107 (i) all patients 6 months after HSCT (a 3-dose series of a vaccine with high tetanus and acellular pertussis content [DTaP] may be more immunogenic and should be considered for the initial vaccination, regardless of patient age, whereas dTap should be used as a booster rather than as part of the primary series); (ii) 3 months after cancer chemotherapy, patients should be vaccinated with dTap, and in regimens that include anti-B-cell antibodies, vaccination should be delayed at least 6 months; (iii) patients with chronic inflammatory illness who are in treatment with immunosuppressive drugs; (iv) HIV-infected patients, based upon their serological status; and (v) SOT candidates or end-stage heart, kidney, liver and lung disease, based upon their serological status.…”

Section: Diphtheria Tetanus Pertussis (Dtp) Vaccinationmentioning

confidence: 99%

See 4 more Smart Citations

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)

Esposito

Bonanni

Maggi

et al. 2016

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Rapid population aging has become a major challenge in the industrialized world and progressive aging is a key reason for making improvement in vaccination a cornerstone of public health strategy. An increase in age-related disorders and conditions is likely to be seen in the near future, and these are risk factors for the occurrence of a number of vaccine-preventable diseases. An improvement in infectious diseases prevention specifically aimed at adults and the elderly can therefore also decrease the burden of these chronic conditions by reducing morbidity, disability, hospital admissions, health costs, mortality rates and, perhaps most importantly, by improving the quality of life. Among adults, it is necessary to identify groups at increased risk of vaccine-preventable diseases and highlight the epidemiological impact and benefits of vaccinations using an evidence-based approach. This document provides clinical practice guidance on immunization for adults in order to provide recommendations for decision makers and healthcare workers in Europe. Although immunization is considered one of the most impactful and cost-effective public health measures that can be undertaken, vaccination coverage rates among adults are largely lower than the stated goal of 95% among adults, and stronger efforts are needed to increase coverage in this population. Active surveillance of adult vaccine-preventable diseases, determining the effectiveness of the vaccines approved for marketing in the last 5 y, the efficacy and safety of vaccines in immunocompromised patients, as well as in pregnant women, represent the priorities for future research.

show abstract

Section: Measles Mumps and Rubella (Mmr) Vaccinationmentioning

confidence: 99%